How much does Ixabepilone cost? latest quote

Ixabepilone is a microtubule stabilizer anti-cancer drug. It was approved by the US FDA in October 2007 for the treatment of patients with metastatic or locally advanced breast cancer, especially those who have progressed after previous treatment with common chemotherapy drugs such as anthracyclines, taxanes and capecitabine. This positioning makes ixabepilone an important member of multi-line treatment. Its application value is mainly reflected in that it is still effective against drug-resistant tumor cells, can delay the development of the disease, and gain more survival time for patients.

Currently, Ixabepilone has not yet been launched in mainland China, so it is not included in the medical insurance catalog. Patients can only obtain it through overseas channels if they need it. According to the data, the specifications in overseas markets are 15mg and 45mg injections, with prices around US$2,000 and US$6,000 respectively, which is relatively expensive in RMB equivalent. Since there are no related generic drugs, prices will be difficult to drop in the short term, which will bring a certain financial burden to patients. Unlike some chemotherapy drugs that have been included in the domestic market, ixabepilone is greatly restricted in terms of accessibility, which is also a regret for breast cancer patients.

In terms of application, ixabepilone is often used in combination with capecitabine to enhance the therapeutic effect, or it can also be used alone as a rescue solution. Its mechanism of action determines that it is still active in some taxane-resistant breast cancers, which is the key to its clinical value. It should be noted that this drug may cause neurological side effects and bone marrow suppression during use, so patients must take standardized medication under the guidance of a doctor.

From the perspective of global drug development trends, although the new generation of targeted drugs and immune drugs have gradually become hot spots in the treatment of breast cancer, ixabepilone still plays an important role in some patient groups. If generic drugs enter the market in the future, prices are expected to drop and more patients can benefit.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html